Kindred Biosciences Receivables

Kindred Biosciences (KIN) currently reports a receivables of $1.6M as of June 2021. That compares with $260K in the prior-year period — up 491.3% year over year. Use the charts on this page to explore Kindred Biosciences's receivables history and peer comparisons.

Kindred Biosciences's receivables increased from $260K to $1.6M — a 491.3% year-over-year increase (period ending June 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Kindred Biosciences reported $1.6M in receivables as of June 2021. That compares with $260K in the prior-year period — up 491.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $1.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Kindred Biosciences, and consider following KIN for alerts when major investors trade the stock.

Kindred Biosciences is classified in the Healthcare sector. On receivables, it currently shows $1.6M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KIN with unrelated industries.